BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 2,020,000 shares, a decline of 16.2% from the October 15th total of 2,410,000 shares. Based on an average daily trading volume, of 997,700 shares, the short-interest ratio is presently 2.0 days.

BioNTech Price Performance

Shares of BNTX traded down $3.84 during mid-day trading on Friday, reaching $99.72. 3,376,703 shares of the stock traded hands, compared to its average volume of 805,347. The firm has a fifty day moving average price of $113.34 and a 200 day moving average price of $97.10. The company has a market cap of $23.91 billion, a price-to-earnings ratio of -45.62 and a beta of 0.26. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 EPS. As a group, equities research analysts predict that BioNTech will post -3.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and lifted their price target for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. UBS Group lifted their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 price target on shares of BioNTech in a report on Thursday. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.54.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. FMR LLC grew its position in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after acquiring an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC purchased a new position in BioNTech in the third quarter worth $59,485,000. Candriam S.C.A. grew its position in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. grew its position in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares in the last quarter. Finally, Braidwell LP purchased a new stake in BioNTech during the third quarter valued at about $29,425,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.